Generics in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2018-23, and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated as averages of countries that comprise the region where volume data exists.
- The UK generics market recorded revenues of $15.5 billion in 2023, representing a compound annual growth rate (CAGR) of 7.2% between 2018 and 2023.
- Market consumption volume increased with a CAGR of 1.3% between 2018 and 2023, to reach a total of 93.8% of total pharma volume in 2023.
- According to the publisher, in 2023, the UK generics market grew by 8.6% annually. The growth is attributed to the country’s mounting aging population. According to the United States Census Bureau, in 2023, the population aged 65 years and above in the UK reached 13.0 million, up 1.8% over 2022.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the United Kingdom
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United Kingdom
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the United Kingdom generics market with five year forecasts by both value and volume
Reasons to Buy
- What was the size of the United Kingdom generics market by value in 2023?
- What will be the size of the United Kingdom generics market in 2028?
- What factors are affecting the strength of competition in the United Kingdom generics market?
- How has the market performed over the last five years?
- How large is the United Kingdom’s generics market in relation to its regional counterparts?
Table of Contents
1 Executive Summary
2 Market Overview
3 Market Data
4 Market Segmentation
5 Market Outlook
6 Five Forces Analysis
7 Competitive Landscape
8 Company Profiles
9 Macroeconomic Indicators
10 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Hikma Pharmaceuticals Plc
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd
- Novartis AG
